RenovoRx (RNXT) AI Stock Analysis

• Market Cap: $38.85M
• Dividend Yield: N/A
• Average Volume (3M): 278.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: N/A
• EPS Growth: 37.89%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 36,649,918
• 10 Day Avg. Volume: 450,908
• 30 Day Avg. Volume: 278,031
• PEG Ratio: 0.13
• Price to Book (P/B): 6.80
• Price to Sales (P/S): 708.18
• P/FCF Ratio: -3.33
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 39.58
• Enterprise Value/Gross Profit: 58.40
• Enterprise Value/Ebitda: -4.59
• 1Y Price Target: $5.63
• Price Target Upside: 430.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $1.00 ▼(-5.66% Downside)

The score is held back primarily by weak financial performance—large operating losses and substantial cash burn despite improving revenue and a low-debt balance sheet. Technicals are comparatively supportive with the stock above major moving averages and positive MACD, while valuation is constrained by negative earnings. The latest earnings call was broadly positive on commercial expansion and trial progress, but this is partially offset by the Nasdaq bid-price compliance risk.

Positive Factors

Proprietary drug‑delivery platform (TAMP)

The TAMP drug‑delivery platform and RenovoCath catheter create a differentiated mode of intra‑arterial chemotherapy delivery. This structural clinical advantage can drive durable adoption at cancer centers, recurring device demand, and partnerships, supporting long‑term commercial scalability.

Phase III progress and DMC backing

Advancing through Phase III with a Data Monitoring Committee recommendation to continue materially reduces development risk. Completing enrollment early 2026 and a clear data timeline to 2027 provide durable regulatory and commercialization visibility for planning trials, partners, and capital needs.

Improving liquidity and low leverage

A cash cushion north of $10M, combined with minimal debt, lowers near‑term refinancing pressure and supports continued commercial expansion and trial enrollment. This balance sheet position gives management runway to execute strategic growth initiatives without immediate dilutive financing.

Negative Factors

High cash burn

Sustained negative operating and free cash flow of roughly $10M annually, versus sub‑$1M revenue, signals a structural funding gap. Absent material revenue scale‑up or spending cuts, ongoing cash burn will force financing that can dilute shareholders and constrain clinical/commercial investment plans.

Large operating and net losses

Deep operating and net losses relative to current revenue reflect an outsized cost base tied to clinical development and early commercialization. Persistent negative profitability undermines return metrics and necessitates sustained capital infusions until revenue scales meaningfully.

Nasdaq bid‑price noncompliance risk

A Nasdaq deficiency notice creates a structural governance and financing risk: management may need to pursue corrective actions (reverse split or other measures) that can reduce liquidity, complicate capital raises, and distract execution, with potential long‑term investor access implications.

RenovoRx Business Overview & Revenue Model

Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

How the Company Makes Money

RenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.

RenovoRx Financial Statement Overview

Summary

RenovoRx is facing significant financial challenges, with persistent losses and negative cash flows. Despite improvements in revenue and equity, the company's core operations remain unprofitable, and it heavily relies on external financing. The balance sheet shows some asset management improvements, but the overall financial health is fragile, with high operational losses posing a significant risk.

Income Statement

RenovoRx shows a slight improvement in revenue with $43,000 reported in the latest year. However, the company faces a challenging profitability situation with a negative net income of $8.8 million and negative EBIT and EBITDA margins, indicating significant operational losses. The gross profit margin is also concerning as it demonstrates no cost of goods sold, which reflects no substantial revenue activities.

Balance Sheet

The balance sheet highlights a modest improvement in stockholders' equity, now at $4.48 million, up from a negative position. However, the company maintains a high leverage with a debt-to-equity ratio of 0.05, which could be considered low in relative terms but is risky in the context of negative profitability. The equity ratio is positive, indicating a shift towards better asset management, but overall financial stability remains a concern.

Cash Flow

Operating cash flow remains negative at $9.13 million, showing consistent cash outflows from operations. Free cash flow is similarly negative, reflecting the company's reliance on financing activities to sustain operations. This cash flow instability poses a risk to long-term sustainability, despite substantial financing inflows in the past year.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	928.00K	43.00K	0.00	0.00	0.00	0.00
Gross Profit	629.00K	43.00K	0.00	0.00	0.00	0.00
EBITDA	-8.01M	-10.97M	-11.39M	-9.94M	-5.48M	0.00
Net Income	-11.11M	-8.81M	-10.23M	-9.89M	-6.32M	-3.80M
Balance Sheet
Total Assets	11.21M	8.12M	1.47M	7.26M	16.29M	1.91M
Cash, Cash Equivalents and Short-Term Investments	10.04M	7.15M	1.17M	6.44M	15.19M	1.79M
Total Debt	236.00K	278.00K	0.00	0.00	0.00	2.79M
Total Liabilities	3.13M	3.64M	4.47M	1.10M	938.00K	16.57M
Stockholders Equity	8.08M	4.48M	-3.00M	6.16M	15.35M	-14.66M
Cash Flow
Free Cash Flow	-10.40M	-9.14M	-10.26M	-8.81M	-5.93M	-3.53M
Operating Cash Flow	-10.38M	-9.13M	-10.26M	-8.81M	-5.92M	-3.53M
Investing Cash Flow	-14.00K	-12.00K	2.03M	-2.03M	-15.00K	0.00
Financing Cash Flow	10.88M	15.12M	5.01M	42.00K	19.33M	3.20M

RenovoRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Positive. The current price of 1.06 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.93, and below the 200-day MA of 1.10, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 58.28 is Neutral, neither overbought nor oversold. The STOCH value of 53.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNXT.

RenovoRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$56.33M	-6.22	-13.15%	―	―	45.97%
PEPG	53 Neutral	$354.05M	-1.82	-62.25%	―	―	4.71%
JSPR	52 Neutral	$45.33M	-0.27	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNXT	51 Neutral	$38.85M	-2.98	-146.61%	―	―	37.89%
OVID	51 Neutral	$117.50M	-3.23	-60.06%	―	946.61%	-11.30%
NRSN	44 Neutral	$31.78M	-1.83	―	―	―	31.09%

RenovoRx Corporate Events

RenovoRx Receives Nasdaq Notice for Bid Price Noncompliance

On December 31, 2025, RenovoRx, Inc. received a deficiency notice from Nasdaq stating that the company’s common stock had failed to meet the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market for 32 consecutive business days, although the notice did not immediately affect the stock’s listing status. The company has been granted an initial 180-day period, until June 30, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days, with the possibility of an additional 180-day extension if it meets other listing standards and commits to corrective actions such as a potential reverse stock split; failure to comply after these periods could lead to delisting proceedings, though the company would have the right to appeal.

The most recent analyst rating on (RNXT) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

RenovoRx Enters Capital on Demand Sales Agreement

On November 14, 2025, RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to issue and sell up to $3,723,029 in shares of its common stock. This agreement, which involves at-the-market offerings or negotiated transactions, is part of RenovoRx’s strategy to leverage its shelf registration statement, extending its ability to raise capital and potentially impacting its market positioning by enhancing financial flexibility.

The most recent analyst rating on (RNXT) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.

RenovoRx Expands Reach with RenovoCath Approval

RenovoRx reported its third-quarter 2025 financial results, highlighting approximately $900,000 in year-to-date revenue and a cash position of $10 million. The company is expanding its commercial reach with the RenovoCath device, now approved in 14 cancer centers, and is advancing its Phase III TIGeR-PaC trial, with enrollment completion expected in early 2026. The company aims to leverage its TAMP platform for long-term growth and improve patient outcomes with targeted therapies.

The most recent analyst rating on (RNXT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.